ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--SensiGen, LLC, a biotechnology company developing proprietary gene-based molecular diagnostics, announced today that the Michigan Economic Development Corporation (MEDC), a nationally recognized state sponsored initiative to promote business formation, expansion, and retention in the State of Michigan, has approved an additional investment in SensiGen to be used for expanding SensiGen’s operations in Ann Arbor. The investment, in the form of a term loan at 1% interest, will be used for hiring workers displaced by the closure of Pfizer’s Michigan based research facilities as part of SensiGen’s planned expansion of operations in the state.